BiotechTube
AVEO Oncology

AVEO Oncology

Boston, United States· Est.
aveooncology.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $280.6M

Overview

AVEO Oncology is a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, operating as a U.S. subsidiary of South Korea's LG Chem. The company has one FDA-approved product, FOTIVDA for renal cell carcinoma, and a diverse early-to-mid-stage pipeline focused on monoclonal antibodies and novel mechanisms. Its business model centers on in-licensing, co-development, and commercialization, aiming to grow into a global oncology leader by leveraging LG Chem's resources and strategic partnerships.

OncologySupportive Care (Cancer Cachexia)

Technology Platform

Historically the HUMAN RESPONSE® Platform for drug development; current pipeline driven by in-licensing and collaboration with LG Chem Innovation Center, focusing on monoclonal antibodies against targets like HGF/c-MET, GDF-15, ERBB3, Notch 3, and LILRB1.

Funding History

5
Total raised:$280.6M
PIPE$53M
Series C$107M
IPO$81.6M
Series B$33M

Opportunities

The major near-term opportunity is expanding the commercial footprint of FOTIVDA in RCC and advancing Ficlatuzumab in HNSCC.
The most significant long-term opportunity lies with Rilogrotug in the vast, untapped market of cancer cachexia, which has no approved therapies.
As LG Chem's U.S.
oncology arm, AVEO has a sustained opportunity to in-license and commercialize a pipeline of novel candidates from its parent and other partners.

Risk Factors

Key risks include clinical failure of pipeline candidates, particularly the novel mechanism of Rilogrotug in cachexia.
The company faces intense competition in all its therapeutic areas, including the crowded RCC market for FOTIVDA.
Execution risks exist in integrating operations with LG Chem and successfully commercializing products in competitive landscapes.

Competitive Landscape

AVEO operates in highly competitive markets. In RCC, FOTIVDA competes with multiple VEGF TKIs, immunotherapy combinations, and newer agents. The HNSCC space is competitive with checkpoint inhibitors and targeted therapies. The cancer cachexia space, while nascent, has several biotechs pursuing different mechanisms. AVEO's differentiation lies in its targeted biologic approach and the financial/strategic backing of LG Chem.

More companies in United States →